BIIB Q2 2022 Earnings — Biogen Inc. Revenue & Financial Results | Market Cap Arena

BIIBBiogen Inc.

$28B

Q2 2022 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$2.6B-6.7% YoY

Gross Profit

$2.1B81.3% margin

Operating Income

$936M36.2% margin

Net Income

$1.1B40.9% margin

EPS (Diluted)

$7.24

QoQ Revenue Growth

+2.3%

Cash Flow

Operating Cash Flow

$737M

Free Cash Flow

$698M

Stock-Based Comp.

$56M

Balance Sheet

Total Assets

$25.1B

Total Liabilities

$13.2B

Stockholders' Equity

$11.9B

Cash & Equivalents

$2.6B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.6B	$2.8B	-6.7%
Gross Profit	$2.1B	$2.3B	-9.1%
Operating Income	$936M	$471M	+98.9%
Net Income	$1.1B	$449M	+135.9%

Revenue Segments

MS Product Revenues

$1.4B44%

Fumarate

$535M16%

TYSABRI product

$516M16%

SPINRAZA

$431M13%

Interferon

$350M11%

Geographic Segments

Non-US

$1.2B56%

UNITED STATES

$894M44%